CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: Implications for its monitoring

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 10, 2009, Pages 1747-1749

  Aleil, B ^a,b   Leon C ^a   Cazenave, J P ^a   Gachet, C ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Clinique de l'Orangerie Strasbourg   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE; VASODILATOR AGENT;

AGED; BLEEDING; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; ENZYME POLYMORPHISM; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; COMORBIDITY; DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; PHYSIOLOGY; POLYPHARMACY; SMOKING;

AGED; ARYL HYDROCARBON HYDROXYLASES; BODY WEIGHT; COMORBIDITY; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; POLYPHARMACY; SMOKING; TICLOPIDINE; VASODILATOR AGENTS;

EID: 70350025236     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03554.x     Document Type: Letter

References (17)

1. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-13.
2. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51:1404-11.
3. Serebruany VL, Oshrine BR, Malinin AI, Atar D, Michelson AD, Ferguson JJ. Noncompliance in cardiovascular clinical trials. Am Heart J 2005, 150:882-6.
4. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schömig A, Schömig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004, 92:311-6.
5. Steinhubl SR, Akers WS. Clopidogrel-statin interaction: a mountain or a mole hill?. Am Heart J 2006, 152:200-3.
6. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-60.
7. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475-84.
8. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109:166-71.
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006, 26:1895-900.
10. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-7.
11. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on clopidogrel platelet reactivity associated with Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. J Am Coll Cardiol 2008, 51:1925-34.
12. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-75.
13. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-62.
14. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-17.
15. Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention. Results from the VASP-02 randomized study. JACC Cardiovasc Interv 2008, 1:631-8.
16. Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance: role of body weight and concomitant medications. Int J Cardiol 2007, 120:188-92.
17. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-15.